Vivoo 스마트 위생 패드

To manage women's reproductive health, it is necessary to understand hormone levels (e.g., FSH) in preparation for pregnancy, irregular menstruation, and menopause. However, existing methods require hospital blood tests or expensive hormone kits. It is difficult to go to the hospital every time, and self-diagnosis is challenging.

Vivoo FlowPad resolves this inconvenience by measuring FSH or infectious disease markers with just one everyday sanitary pad, enabling periodic monitoring.

Menstrual blood is automatically diluted and processed using a microfluidic structure, and then the FSH concentration is measured by a reaction layer that changes color through a window on the back of the pad. In other words, simply wearing it like a common sanitary pad allows you to check your hormone levels without separate blood collection or reagent processing.

The results can also be analyzed with a smartphone app, which indirectly checks ovarian reserve, hormone imbalance, and infection status. Compared to existing self-hormone kits, it offers superior comfort and hygiene, and is planned to be supplied at the price level of disposable sanitary pads (approximately $3-5).

B2C (general women, menstrual cycle observers) and medical/healthcare fields (obstetrics and gynecology, clinical researchers) may also be included. It can be easily used by individuals during menstruation and is well-suited for use as an auxiliary material for gynecological treatment. Corporate welfare or subscription service models through insurance companies are also possible.

As a product targeting female customers worldwide, it has broad marketability, except for some countries with different sanitary pad standards. Medical device approval (FDA, CE certification), personal information protection, and verification of the stability of biochemical reagents are key.

Initially, it focuses on specific hormones (follicle-stimulating hormone), but future expansion of functions such as vaginitis and pregnancy monitoring is possible, allowing expansion into the overall women's healthcare market.

As a CES Digital Health Award winner, its technical novelty was highly evaluated. In terms of completeness, it is at the prototype level but is expected to be commercialized soon.

The market expects low prices and convenience to be strengths, but concerns about accuracy verification and ethical/privacy issues are also mentioned. The reliability of hormone test results and personal information security are identified as challenges. Currently in the "early stages of development"."Market verification is insufficient"on the one hand.